




Confidential

P&P

2009.02.24

Pharma-pia Co.,Ltd





# Company Overview

<b>Name</b>	Pharma-Pia Co. Ltd.	<b>Employee</b>	12
<b>CEO</b>	Shin, Yon-Hee & Moon, Gyu-Youn	<b>Established</b>	Sep. 2002
		<b>TEL</b>	82-2-425-0871
<b>Type</b>	Wholesaler, Developer	<b>FAX</b>	82-2-425-0873
<b>Address</b>	#310, Jamsilbon-Dong, Songpa-gu, Seoul, Korea		
<b>Web</b>	<a href="http://www.pharma-pia.com">www.pharma-pia.com</a>		
<b>Major Business</b>	<ul style="list-style-type: none"><li>* Licensing and Domestic Marketing of Foreign technology</li><li>* Custom synthesis of API and health supplement raw material.</li><li>* Developing and Distribution of Finished Formulation</li><li>* International Marketing of API</li></ul>		



# History

<b>History</b>	
<b>Sep. 2002</b>	<b>Established Pharma-pia Co.,Ltd</b>
<b>Dec. 2002</b>	<b>Acquired wholesale license of medical raw material Designed as the best qualified company by KGSP (Korea Good Supplying Practice)</b>
<b>Aug. 2004</b>	<b>Obtained trade and drug import-export business license</b>
<b>Jul. 2005</b>	<b>Agreement technical tie-up contract with FineChem Corp.(synthesis specialist Venture Enterprise)</b>
<b>Aug. 2005</b>	<b>Increased the capital to 525 million won</b>
<b>Sep. 2005</b>	<b>Acquired wholesale license of Finished Formulation</b>
<b>Dec. 2005</b>	<b>Export contract with Veitnam for API</b>
<b>Apr. 2007</b>	<b>Factory site planning (10,000 m<sup>2</sup>) In JeCheon Bio Industrial Zone</b>
<b>Dec. 2007</b>	<b>Registered KDMF - Glimepride (Medichem, Spain)</b>
<b>Jun. 2008</b>	<b>Registered KDMF - Aceclofenac (Amoli Organics, India)</b>
<b>May. 2009</b>	<b>MOU with SusungPharm</b>

## Factory site planning





# Business Profile

## Licensing and Domestic Marketing of Foreign technology

<b>Donepezil HCl</b>	<b>Israel</b>	<b>Rosuvastatin Ca</b>	<b>China</b>
<b>Mosapride Citrate</b>	<b>India</b>	<b>Risedronate Sodium</b>	<b>India</b>
<b>Moniflumate</b>	<b>Korea</b>	<b>Olmesartan</b>	<b>Korea</b>
<b>Pioglitazone</b>	<b>India</b>	<b>Chlorquinaldol</b>	<b>China</b>
<b>Tacrolimus</b>	<b>India</b>	<b>Glimepride</b>	<b>Spain</b>
<b>Tramadol HCl</b>	<b>India</b>	<b>Ibandronate Sodium</b>	<b>India</b>
<b>Leflunomide</b>	<b>Taiwan</b>	<b>Itraconazole</b>	<b>India</b>
<b>Mycophenolate mofetil</b>	<b>Taiwan</b>	<b>Oxiracetam</b>	<b>China</b>
<b>Valsartan</b>	<b>India</b>	<b>Magnesium Dimecrotate</b>	<b>Korea</b>
<b>Montelukast</b>	<b>India</b>	<b>Sofalcon</b>	<b>Korea</b>
<b>Levocetirizine DiHCl</b>	<b>India</b>	<b>Light Kaolin</b>	<b>UK</b>



## Business Profile (Continued)

### Developing and Distribution of Finished Formulation


Agreement with Martek Biosciences Corp	USA	Algae DHA Oil
Agreement with Columbia Laboratories Inc	USA	Striant
Agreement with DEHLY SA	Swiss	PhytAlma
Agreement with Umedica laboratories	India	Cefotaxime
Agreement with QuattroTi DenTech Srl	Italy	Dr.BruX

### International Marketing of API

Yr2006 Exporting API \$400,000

Yr2007 Exporting API \$500,000

Yr2008 Exporting API \$250,000



# Marketing

<b>Yearly Sales (\$)</b>	
Yr2003	2.4 M
Yr2004	4.8 M
Yr2005	6.0 M
Yr2006	7.0 M
Yr2007	9.4 M
Yr2008	16.0 M

